New company grows out of Gene Editing Institute to accelerate discovery and innovation Article Site: ChristianaCare ChristianaCare’s Gene Editing Institute has launched DECODR, Inc., a new for-profit company created to expand access to one of the world’s leading software tools to evaluate the effectiveness of CRISPR gene editing. The software program grew out of the Gene Editing Institute’s mission to turn cutting edge science into real world solutions that helps patients. No

Eric B. Kmiec, PhD The recent approval by the U.S. Food and Drug Administration (FDA) of Casgevy, a therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics that uses CRISPR gene editing to treat patients with sickle cell disease, is a watershed moment in the history of this nascent field. I have been involved in gene therapy research for decades. Like many of my peers, I am thrilled that with this incredible breakthrough, CRISPR may be, as one story in GEN noted,